<DOC>
<DOCNO>EP-0637586</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)-benzofuran-7-carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D30786	A61K3144	C07D40500	A61K31445	A61K31443	A61P2502	A61P4300	A61K314427	A61K31445	C07D30700	A61P2100	A61P2100	A61P4300	A61P2500	A61P2528	A61K3144	C07D40504	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61K	C07D	A61K	A61K	A61P	A61P	A61K	A61K	C07D	A61P	A61P	A61P	A61P	A61P	A61K	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D307	A61K31	C07D405	A61K31	A61K31	A61P25	A61P43	A61K31	A61K31	C07D307	A61P21	A61P21	A61P43	A61P25	A61P25	A61K31	C07D405	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
2-(piperidin-4-yl, pyridin-4-yl and 
tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives of the 

formula I 

wherein 

R₁
is hydrogen, loweralkyl, arylloweralkyl, CONHR₅ or 
CONR₆R₇ 
R₂
is hydrogen, cyano, CH₂NR₈R₉, CONHR₅ 
or CONR₆R₇; 
R₃
is 

 
where R₁₀ is hydrogen, loweralkyl, arylloweralkyl, 

CONHR₅, CONR₆R₇, acyl, acyloxyloweralkyl or 
acyloxyarylloweralkyl; 
R₄
is hydrogen, halogen, loweralkyl or loweralkoxy; 
R₅
is hydrogen, loweralkyl or arylloweralkyl; 
R₆
is loweralkyl or arylloweralkyl; 
R₇
is loweralkyl or arylloweralkyl; 
R₈
is hydrogen, loweralkyl, arylloweralkyl or acyl; 
R₉
is hydrogen, loweralkyl or arylloweralkyl; 
R₁₁
is loweralkyl, aryl or arylloweralkyl; 
with the proviso that if R₁ is hydrogen or loweralkyl, R₂ 
cannot be hydrogen; or a pharmaceutically acceptable acid addition salt 

thereof, or where applicable, an optical or geometric isomer or racemic 
mixture thereof, which are useful as 

acetylcholinesterase inhibitors and as such may be useful for the 
treatment of Alzheimer's 

disease and other senile dementias. 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention relates to 2-(piperidin-4-yl, pyridin-4-yl and
tetrahydropyridin-4-yl)benzofuran-7-yl carbamate derivativesEP-A-165 810 and EP-A-338 782 describe 2-(pyridin-4-yl)benzofuran
derivatives as inhibitors of leukotriene biosynthesis for use in the treatment of
conditions such as asthma and cardiovascular disorders.US-A-4-210 655 describes 2-(piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran
derivatives for use in the treatment of mental depression.EP-A-542 671 describes 4-(7-halo-5-alkoxy-benzofuran-2-yl)piperidines having
antidepressant activity and processes for their preparation.EP-A-398 413 describes 3-(7-benzo[b]furanyl)-3,4-dehydropiperidine and
related derivatives having psychotropic activity.EP-A-217 530 describes a class of compounds including benzofurans bearing a
dihydropyridine moiety which are stated to have vasodilator activity.EP 6524 describes benzofurans bearing a piperidine or tetrahydropyridine
moiety in the 4, 5, 6 or 7-position which have antidepressant activity.The present invention particularly relates to compounds of the general formula I

wherein
R1 is CONHR11 or CONR6R7R3 is

where
R10 is hydrogen or C1-C6-alkyl.R6 is C1-C6-alkyl,R7 is C1-C6-alkyl, andR11 is C1-C6-alkyl 
   or a pharmaceutically acceptable acid addition salt thereof, or, where applicable,
an optical or geometric isomer or racemic mixture thereof.Additionally, this invention also relates to pharmaceutical compositions
containing compounds of the above formula and to their use as
acetylcholinesterase inhibitors.Unless otherwise stated or indicated, the following definitions shall apply
throughout the specification and appended claims.The term "lower" or "C1-C6" shall mean the group it is describing contains from
1 to 6 carbon atoms.The term "loweralkyl" or "C1-C6-alkyl" shall mean a straight or branched alkyl
group having from 1 to 6 carbon atoms, e.g., methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, t-butyl and straight and branched chain pentyl and
hexyl.The term halogen shall mean fluorine, chlorine, bromine or iodine.Throughout the specification and appended claims, a given chemical formula or
name shall encompass all stereo and optical isomers where such isomers exist.Additionally, a given chemical formula or name shall encompass the
pharmaceutically acceptable addition salts thereof. In a preferred embodiment of this invention are compounds of the formula I
wherein R10 is C1-C6-alkyl.The following compounds are particularly preferred:
a. A compound of
</DESCRIPTION>
<CLAIMS>
A compound of the formula I


wherein

R
1
 is CONHR
11
 or CONR
6
R
7
R
3
 is


where

R
10
 is hydrogen or C
1
-C
6
-alkyl
R
6
 is C
1
-C
6
-alkyl,
R
7
 is C
1
-C
6
-alkyl and
R
11
 is C
1
-C
6
-alkyl

or a pharmaceutically acceptable acid addition salt thereof, or, where
applicable, optical or geometric isomers or racemic mixtures thereof.
A compound of the formula I as claimed in claim 1 wherein R
10
 is C
1
-C
6
alkyl.
A compound of the formula I as claimed in claim 1 which is:
2-(1-methyl-4-piperidinyl)-benzofuran-7-yl methyl carbamate.
A compound of the formula I as claimed in claim 1 which is:
2-(4-pyridinyl)benzofuran-7-yl methyl carbamate
A compound of the formula I as claimed in claim 1 which is:
2-(1-methyl-4-piperidinyl)-benzofuran-7-yl diethyl carbamate. 
A pharmaceutical composition which comprises an effective amount of a
compound as claimed in any one of claims 1 to 5 and a pharmaceutically

acceptable carrier therefor.
The use of a compound as claimed in any one of claims 1 to 5 as a
pharmaceutical.
The use of a compound as claimed in any one of claims 1 to 5 for the
production of a pharmaceutical having an activity as acetyl

cholinesterase inhibitor
</CLAIMS>
</TEXT>
</DOC>
